DC-CIK细胞免疫联合阿帕替尼治疗肝癌的临床效果

Clinical Effect of DC-CIK Cellular Immunity Combined with Apatinib in the Treatment of Liver Cancer

目的:分析肝癌患者肿瘤免疫治疗中实施树突状细胞-细胞因子诱导的杀伤细胞(DC-CIK细胞)免疫治疗的临床疗效。方法:选取2019年1月-2022年4月河北省涿州市医院收治的肝癌患者80例为研究对象,应用随机数表法分为常规组与研究组,各40例。常规组以阿帕替尼治疗,研究组以DC-CIK细胞免疫联合阿帕替尼治疗。对比两组治疗效果。结果:治疗后,研究组免疫功能指标、血清指标、临床疗效均优于常规组,差异具有统计学意义(P<0.05)。研究组不良反应发生率与常规组比较,差异无统计学意义(P>0.05)。结论:肝癌患者在肿瘤免疫治疗中应用DC-CIK细胞免疫,可显著提高临床疗效,改善各项临床指标,且安全性较高。

Objective:To analyze the clinical efficacy of dendritic cell-cytokine-induced killer cell(DC-CIK cell)immunotherapy in patients with liver cancer.Methods:A total of 80 patients with liver cancer who were admitted to Zhuozhou Hospital of Hebei Province from January 2019 to April 2022 were selected as the research objects.The patients were divided into a routine group and a study group by random number table method,with 40 cases in each group.The routine group was treated with apatinib,and the study group was treated with DC-CIK cell immunization combined with apatinib.The treatment effects of the two groups were compared.Results:After treatment,the immune function indexes,serum indexes and clinical efficacy of the study group were better than those of the routine group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the study group and the routine group(P>0.05).Conclusion:The application of DC-CIK cell immunization in tumor immunotherapy for liver cancer patients can significantly improve the clinical efficacy,improve various clinical indicators,and has high safety.